Physician profile
Daniela E Rusovici
NPI 1801964788
$2,939.15
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,378 · 2020: $547 · 2022: $14.18.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $417.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $272.05 | 2019 | |
| Ucb, INC. | $232.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $216.35 | 2019-2020 | |
| Amgen INC. | $215.31 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $212.35 | 2019-2020 | |
| Emd Serono, INC. | $189.71 | 2019-2020 | |
| Genzyme Corporation | $138.70 | 2019-2020 | |
| Allergan, INC. | $124.60 | 2019-2020 | |
| Mdd US Operations, LLC | $124.24 | 2019 | |
| Acadia Pharmaceuticals INC | $109.02 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $105.76 | 2019-2020 | |
| Eisai INC. | $76.55 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $64.03 | 2019 | |
| Lundbeck LLC | $61.82 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $55.03 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $39.49 | 2019 | |
| Livanova USA, INC. | $37.39 | 2019-2020 | |
| Pfizer INC. | $35.16 | 2019 | |
| Supernus Pharmaceuticals, INC. | $25.30 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $24.81 | 2019-2020 | |
| Sk Life Science, INC. | $23.98 | 2020 | |
| Biogen, INC. | $21.16 | 2020 | |
| Csl Behring | $19.06 | 2019 | |
| Acorda Therapeutics, INC | $18.64 | 2019 | |
| Ermi LLC | $17.93 | 2020 | |
| Tanabe Pharma America, INC. | $16.64 | 2020 | |
| Greenwich Biosciences, INC. | $16.12 | 2019 | |
| Abbvie INC. | $14.18 | 2022 | |
| Genentech USA, INC. | $12.88 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Rusovici listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.